Litcius/Paper detail

Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis

Monika Sparber‐Sauer, Daniel Orbach, Fariba Navid, Simone Hettmer, Stephen X. Skapek, Nadège Corradini, Michela Casanova, Aaron R. Weiss, Matthias Schwab, Andrea Ferrari

2021British Journal of Cancer30 citationsDOIOpen Access PDF

Topics & Concepts

MedicineSorafenibPazopanibImatinibFibromatosisAggressive fibromatosisOncologyTyrosine kinaseClinical trialInternal medicinePharmacologySurgerySunitinibCancerMyeloid leukemiaHepatocellular carcinomaReceptorSoft tissue tumor case studiesSarcoma Diagnosis and TreatmentNeurofibromatosis and Schwannoma Cases
Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis | Litcius